According to a recent LinkedIn post from Hemanext, the company is drawing attention to hypoxic storage as a method to preserve red blood cell quality over the full 42‑day storage period. The post cites scientific literature suggesting that reducing oxygen exposure may limit oxidative damage, maintain metabolic markers such as ATP and 2,3‑DPG, and support better red cell functionality at transfusion.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights Hemanext ONE as a system designed to enable this hypoxic storage approach and positions it as a potential tool for clinicians seeking more consistent blood quality. For investors, this emphasis on scientific validation and product design suggests a focus on differentiation in transfusion medicine, which could support future commercialization prospects if regulatory, reimbursement, and adoption hurdles are successfully addressed.
The post also underscores a broader trend toward technology‑driven quality improvements in blood banking and transfusion care. If hypoxic storage gains clinical and economic traction, Hemanext could benefit from early positioning in this niche, although outcomes will depend on clinical data, healthcare system uptake, and competitive responses within the blood technology space.